---
title: "JINLEI released its first-quarter performance, with a net profit attributable to the parent company of 55.9109 million yuan, an increase of 91.17%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237696745.md"
description: "JINLEI released its Q1 2025 performance, with operating revenue of 505 million yuan, a year-on-year increase of 97.54%; net profit attributable to shareholders of the parent company was 55.9109 million yuan, a year-on-year increase of 91.17%; net profit excluding non-recurring gains and losses was 53.158 million yuan, a year-on-year increase of 127.22%; basic earnings per share were 0.1746 yuan"
datetime: "2025-04-27T09:26:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237696745.md)
  - [en](https://longbridge.com/en/news/237696745.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237696745.md)
generator: "portal-rs"
---

# JINLEI released its first-quarter performance, with a net profit attributable to the parent company of 55.9109 million yuan, an increase of 91.17%

According to the Zhitong Finance APP, JINLEI (300443.SZ) released its first-quarter report for 2025, showing an operating income of 505 million yuan, a year-on-year increase of 97.54%. The net profit attributable to shareholders of the listed company was 55.9109 million yuan, a year-on-year increase of 91.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 53.158 million yuan, a year-on-year increase of 127.22%. The basic earnings per share were 0.1746 yuan

### Related Stocks

- [300443.CN](https://longbridge.com/en/quote/300443.CN.md)

## Related News & Research

- [Number of shares and votes in BioArctic AB (publ) as of August 31, 2026](https://longbridge.com/en/news/297542152.md)
- [The unhelpful nationalism of ‘Buy British’ in defence](https://longbridge.com/en/news/297465532.md)
- [04:14 ETThe Anime "KAGURABACHI" Casts Miku Ito as Hinao and Miyari Nemoto as Char Kyonagi; Cast Comments, Character Visuals & Trailers Revealed](https://longbridge.com/en/news/297287110.md)
- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)
- [HBM Healthcare Investments posts Aug NAV CHF 302.32, up 2% MTD](https://longbridge.com/en/news/297674839.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**